Insights Blog
Explore our thought leadership insights, as life science technologies evolve and accelerate.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Blog Article
Research Tools
AGBT 2024: DeciBio Highlights – NGS Reclaims the Spotlight
February 9, 2024
Blog Article
Research Tools
AGBT 2024: DeciBio Highlights – NGS Reclaims the Spotlight
February 9, 2024
Research Tools
Spatial Omics
Newsletter Update
Clinical Diagnostics
Liquid Biopsy | January Roundup 2024
2024 ushered in a lot of Liquid Biopsy (LBx) news, especially within MRD! January brought several collaborations, new study results, and legal decisions.
February 9, 2024
Newsletter Update
Clinical Diagnostics
Liquid Biopsy | January Roundup 2024
2024 ushered in a lot of Liquid Biopsy (LBx) news, especially within MRD! January brought several collaborations, new study results, and legal decisions.
February 9, 2024
Liquid Biopsy
.png)
Newsletter Update
Pharma & Biotech
Next-Generation Therapeutics Newsletter | January Roundup 2024
Read about the latest updates in the Next-Generation Therapeutics space in the month of January.
February 1, 2024
Newsletter Update
Pharma & Biotech
Next-Generation Therapeutics Newsletter | January Roundup 2024
Read about the latest updates in the Next-Generation Therapeutics space in the month of January.
February 1, 2024
Next-Generation Therapeutics
In The Press
Pharma & Biotech
Trailblazing Impact of Antibody-Drug Conjugates
The field of Antibody-Drug Conjugates (ADCs) has experienced a remarkable transformation, shifting from dormancy to a surge in technological advancements.
January 31, 2024
In The Press
Pharma & Biotech
Trailblazing Impact of Antibody-Drug Conjugates
The field of Antibody-Drug Conjugates (ADCs) has experienced a remarkable transformation, shifting from dormancy to a surge in technological advancements.
January 31, 2024
adjuvant cell therapy
DeciBio Q&A
Pharma & Biotech
Training Cell Therapies: DeciBio Q&A with Brian Feth (CEO) and James Lim (CSO) of Xcell Biosciences
In this Q&A with Brian Feth (CEO) and James Lim (CSO) of Xcell Biosciences, they share their journey into cell therapies, discussing the need for tools to modulate conditions, the critical step in enabling cell therapies to target solid tumors, and the importance of automation and bespoke manufacturing workflows in advancing the field.
January 17, 2024
DeciBio Q&A
Pharma & Biotech
Training Cell Therapies: DeciBio Q&A with Brian Feth (CEO) and James Lim (CSO) of Xcell Biosciences
In this Q&A with Brian Feth (CEO) and James Lim (CSO) of Xcell Biosciences, they share their journey into cell therapies, discussing the need for tools to modulate conditions, the critical step in enabling cell therapies to target solid tumors, and the importance of automation and bespoke manufacturing workflows in advancing the field.
January 17, 2024
Cell & Gene Tx
Infographic
Clinical Diagnostics
DeciBio NGS DxBook - Solid Tumor Panels
The evolving landscape of NGS in clinical oncology reveals intriguing trends, especially for solid tumor panels.
January 15, 2024
Infographic
Clinical Diagnostics
DeciBio NGS DxBook - Solid Tumor Panels
The evolving landscape of NGS in clinical oncology reveals intriguing trends, especially for solid tumor panels.
January 15, 2024
DeciBio News
DxBooks Data Insights
Precision Medicine is evolving at a rapid pace
Discover how we can help
Get in Touch
© DeciBio 2023 | All rights reserved